This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
监管记录显示,特沙莫瑞林于 2010 年在美国首次获得批准,用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验,而非体重或瘦体重的普遍改善。后续出现了不同制剂版本,但其核心适应症保持一致。关于长期心血管结局和死亡率影响,现有证据仍不充分。
在临床研究之外,特沙莫瑞林常被讨论为生长激素分泌促进剂,但这一说法需要限定。它并不等同于生长激素本身,也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力,另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中,尚未形成统一结论。
特沙莫瑞林是一种合成肽,其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰,这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂,可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物,而非小分子化合物。
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成肽 | 含 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 用于抵抗二肽基肽酶 IV 降解 |
| 首次批准 | 2010 年,美国 | 用于 HIV 相关脂肪营养不良 |
| 作用靶点 | 生长激素释放激素受体 | 位于垂体前叶 |
| 主要研究终点 | 内脏脂肪变化 | 非总体重或瘦体重 |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
=== FTIR as detector in chromatography === The speed of FTIR allows spectra to be obtained from compounds as they are separated by a gas chromatograph. However this technique is little used compared to GC-MS (gas chromatography-mass spectrometry) which is more sensitive. The GC-IR method is particularly useful for identifying isomers, which by their nature have identical masses. Liquid chromatography fractions are more difficult because of the solvent present. One notable exception is to measure chain branching as a function of molecular size in polyethylene using gel permeation chromatography, which is possible using chlorinated solvents that have no absorption in the area in question.
In Britain, a half and half may mean a mixture of mild ale and bitter. In the North East of England, a request for a half and half would more commonly produce a combination of Scotch ale and India pale ale (IPA). This drink fell from favour when the Scottish & Newcastle brewery was obliged to sell many of their tied public houses and McEwan's Scotch and IPA disappeared from public bars across the North East. In Canada and the United States, Black and Tan refers to Guinness and a lager or ale that will support the Guinness, most commonly Bass Ale, although some Irish-themed bars shun the term for its association with the Royal Irish Constabulary's "Black and Tans" force. A Half and Half is Guinness and Harp. A Guinness and Smithwick's is a Blacksmith.
The hazards of synthetic biology include biosafety hazards to workers and the public, biosecurity hazards stemming from deliberate engineering of organisms to cause harm, and environmental hazards. The biosafety hazards are similar to those for existing fields of biotechnology, mainly exposure to pathogens and toxic chemicals, although novel synthetic organisms may have novel risks. For biosecurity, there is concern that synthetic or redesigned organisms could theoretically be used for bioterrorism. Potential risks include recreating known pathogens from scratch, engineering existing pathogens to be more dangerous, and engineering microbes to produce harmful biochemicals. Lastly, environmental hazards include adverse effects on biodiversity and ecosystem services, including potential changes to land use resulting from agricultural use of synthetic organisms. Synthetic biology is an example of a dual-use technology with the potential to be used in ways that could intentionally or unintentionally harm humans and/or damage the environment. Often "scientists, their host institutions and funding bodies" consider whether the planned research could be misused and sometimes implement measures to reduce the likelihood of misuse. Existing risk analysis systems for GMOs are generally considered sufficient for synthetic organisms, although there may be difficulties for an organism built "bottom-up" from individual genetic sequences.
Vernon Bogdanor (born 16 July 1943); author, academic, scholar, political scientist, historian, and research professor at the Institute for Contemporary British History at King's College London; emeritus professor of politics and government at the University of Oxford and an emeritus fellow of Brasenose College, Oxford; appointed Commander of the Order of the British Empire (CBE) in the 1998 Birthday Honours for services to constitutional history; appointed a Chevalier de la Légion d'honneur by president of France, Nicolas Sarkozy; was knighted in 2023 New Year Honours for services to political science. David Bohm (20 December 1917 – 27 October 1992) American British scientist and prolific author described as one of the most significant theoretical physicists of the 20th century, who contributed unorthodox ideas to quantum theory, neuropsychology and the philosophy of mind, of Hungarian Jewish origin. Alain de Botton popular author, broadcaster and YouTube channel entrepreneur, of Ashkenazi and Sephardic ancestry. He co-founded The School of Life. Botton is the son of Gilbert de Botton and descended from a distinguished Sephardic Jewish family; among his ancestors were the rabbinical scholar Abraham de Boton and Yolande Harmer journalist and Israeli intelligence officer.
Ceruloplasmin is an acute phase protein synthesized in the liver. It is the carrier of the copper ion. Its level is increased in infections, rheumatoid arthritis, pregnancy, non-Wilson liver disease and obstructive jaundice. In Wilson disease, the ceruloplasmin level is depressed which lead to copper accumulation in body tissues.
Sources: en.wikipedia.org
== Lignin == Lignin is a complex polyphenolic macromolecule composed mainly of beta-O4-aryl linkages. After cellulose, lignin is the second most abundant biopolymer and is one of the primary structural components of most plants. It contains subunits derived from p-coumaryl alcohol, coniferyl alcohol, and sinapyl alcohol, and is unusual among biomolecules in that it is racemic. The lack of optical activity is due to the polymerization of lignin which occurs via free radical coupling reactions in which there is no preference for either configuration at a chiral center.
== Use during the 20th century == During the 20th century its use declined as governments regulated its ingredients (opium is a controlled substance in many countries). Beginning in late 2011, there was a period in which paregoric was not being manufactured in the United States. As of August 2012, however, the manufacture of paregoric had resumed.
Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces filamentosus. Daptomycin consists of 13 amino acids, 10 of which are arranged in a cyclic fashion, and three on an exocyclic tail. Two nonproteinogenic amino acids exist in the drug, the unusual amino acid L-kynurenine (Kyn), only known to daptomycin, and L-3-methylglutamic acid (mGlu). The N-terminus of the exocyclic tryptophan residue is coupled to decanoic acid, a medium-chain (C10) fatty acid. Biosynthesis is initiated by the coupling of decanoic acid to the N-terminal tryptophan, followed by the coupling of the remaining amino acids by nonribosomal peptide synthetase (NRPS) mechanisms. Finally, a cyclization event occurs, which is catalyzed by a thioesterase enzyme, and subsequent release of the lipopeptide is granted. The NRPS responsible for the synthesis of daptomycin is encoded by three overlapping genes, dptA, dptBC and dptD. The dptE and dptF genes, immediately upstream of dptA, are likely to be involved in the initiation of daptomycin biosynthesis by coupling decanoic acid to the N-terminal Trp. These novel genes (dptE, dptF) correspond to products that most likely work in conjunction with a unique condensation domain to acylate the first amino acid (tryptophan). These and other novel genes (dptI, dptJ) are believed to be involved in supplying the nonproteinogenic amino acids L-3-methylglutamic acid and Kyn; they are located next to the NRPS genes. The decanoic acid portion of daptomycin is synthesized by fatty acid synthase machinery (Figure 2).
It is responsible for the decarboxylation of α-keto acids formed by the transamination of valine, leucine, and isoleucine and produces the primers used for branched-chain fatty acid synthesis. The activity of this enzyme is much higher with branched-chain α-keto acid substrates than with straight-chain substrates, and in Bacillus species its specificity is highest for the isoleucine-derived α-keto-β-methylvaleric acid, followed by α-ketoisocaproate and α-ketoisovalerate. The enzyme's high affinity toward branched-chain α-keto acids allows it to function as the primer donating system for branched-chain fatty acid synthetase.
Sources: en.wikipedia.org
=== Essendon === On 24 August 2026, McVeigh was appointed the senior coach of the Essendon Football Club on the three year contract, returning to the club where he played his entire playing career. McVeigh replaced caretaker senior coach Dean Solomon, who replaced senior coach Brad Scott after Scott was sacked in the middle of the 2026 AFL season.
=== Ligand-based === Ligand-based drug design (or indirect drug design) relies on knowledge of other molecules that bind to the biological target of interest. These other molecules may be used to derive a pharmacophore model that defines the minimum necessary structural characteristics a molecule must possess in order to bind to the target. A model of the biological target may be built based on the knowledge of what binds to it, and this model in turn may be used to design new molecular entities that interact with the target. Alternatively, a quantitative structure-activity relationship (QSAR), in which a correlation between calculated properties of molecules and their experimentally determined biological activity, may be derived. These QSAR relationships in turn may be used to predict the activity of new analogs.
Historically, it has been used in fermentation, specifically to ferment soybean and create tempeh in Malaysia and Indonesia. Using the same methods to create traditional tempeh, R. oryzae can be inoculated in other cooked legumes such as peas, beans, and fava beans. Similarly in tempeh making, there is an initial bacterial fermentation in legumes when they are soaked for a while before being cooked. Fermentation incubation lasts for 48 hours at 33 °C. After incubation, mycelium can be observed between the legumes creating a larger, uniform product. Overall, fruits, grains, nuts, and legumes mold-fermentation with R. oryzae produces sensory changes in foods such as creating acidity, sweetness and bitterness. R. oryzae can produce lactate from glucose at high levels, which is used as a food additive and can also degrade plastics. In enzyme-modified cheese products, R. oryzae provides microbial enzymes where milk fat and proteins are broken down to create powder and paste forms of cheese. Specifically, it breaks down cheese curds and acid casein. Among finding cellulases and hemicellulases, other enzymes such as protease, urease, ribonuclease, pectate lyase, and polygalacturonase are found in cultural media of R. oryzae. Besides producing a number of enzymes, it can also produce a number of organic acids, alcohol, and esters. Cellulases in R. oryzae can be applied to biotechnology, in food, brewery and wine, animal feed, textiles and laundry, pulp and paper industries, and agriculture. R.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
== External links == "Paclitaxel". National Cancer Institute. 5 October 2006. "Paclitaxel". NCI Drug Dictionary. 2 February 2011. Molecule of the Month: TAXOL by Neil Edwards, University of Bristol. A Tale of Taxol from Florida State University. Berenson A (1 October 2006). "Hope, at $4,200 a Dose". The New York Times. Retrieved 31 March 2007.
Sources: en.wikipedia.org
特沙莫瑞林是国际非专利名称,指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽,序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。
监管批准集中于 HIV 感染相关的脂肪营养不良,目的是减少内脏脂肪。它未被批准用于普通肥胖或一般体重管理。不同国家的批准状态和标签范围可能不同。
长期心血管获益、死亡率影响以及停药后的持续性仍缺乏确证。部分研究提示 IGF-1 和血糖参数可能变化,但个体差异较大。这些开放问题需要更长期、更大规模的试验来回答。
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.